2019
DOI: 10.1080/14712598.2019.1564034
|View full text |Cite
|
Sign up to set email alerts
|

Characteristics of biological therapy in pediatric patients with Crohn’s disease

Abstract: Introduction: At present, there a is significant amount of data related to biologics used in pediatric patients with Crohn's disease. This review characterizes the different biological drugs administered in this population.Areas covered: Biological therapy of CD, focusing on children, is summarized in this review. After mechanism of action and pharmacokinetics are described, mucosal healing on anti-TNF therapy, aspects of early therapy, long-term outcome and combination therapy are discussed. Moreover, loss of… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
3
1
1

Citation Types

0
4
0
2

Year Published

2019
2019
2023
2023

Publication Types

Select...
7
1

Relationship

0
8

Authors

Journals

citations
Cited by 8 publications
(7 citation statements)
references
References 129 publications
0
4
0
2
Order By: Relevance
“…In recent years, biological therapies have begun to be used in the pediatric population, and these approaches currently play a key role in the management of several diseases. The management of PD has improved since the introduction of these therapies, reducing the number of surgical procedures and improving the quality of life of patients (9)(10)(11) .…”
Section: O R I G I N a L A R T I C L Ementioning
confidence: 99%
See 1 more Smart Citation
“…In recent years, biological therapies have begun to be used in the pediatric population, and these approaches currently play a key role in the management of several diseases. The management of PD has improved since the introduction of these therapies, reducing the number of surgical procedures and improving the quality of life of patients (9)(10)(11) .…”
Section: O R I G I N a L A R T I C L Ementioning
confidence: 99%
“…Anti-TNFα treatment is currently recommended as induction therapy for children with active perianal fistulizing disease; when necessary, anti-TNFα may be combined with surgery (11) . We observed an increased risk for biological therapy in children with perianal findings.…”
Section: Use Of Biological Therapymentioning
confidence: 99%
“…En los últimos años, las terapias biológicas han empezado a emplearse en la población pediátrica, hasta el punto de que estos abordajes desempeñan actualmente un papel fundamental en el manejo de diversas enfermedades. El manejo de la EP ha mejorado desde la introducción de estas terapias, que han reducido el número de cirugías y mejorado la calidad de vida de los pacientes (9)(10)(11) .…”
Section: Introductionunclassified
“…While guidelines have been developed for the treatment of CD and UC populations, questions remain regarding the appropriate selection, monitoring, and switching rules for both biologic and biosimilar use in individual patients [4][5][6][7]. Based on disease severity at initial presentation, patients are started often on a biologic or combinations of biologics (i.e., agents with different mechanisms of action, such as combining an anti-TNF-α and an anti-integrin or anti-IL 12/23) instead of steroids and immunomodulators, especially in children [8][9][10][11]. In fact, higher rates of morbidity and mortality have been observed in patients treated with prolonged steroids compared to biologics [12].…”
Section: Introductionmentioning
confidence: 99%